Symbols / APM $0.80 +1.32%

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Price estimates from analyst targets and simple models.

• Blood test study takes aim at glioblastoma, deadliest brain cancer - Stock Titan ue, 10 Mar 2026 12
• Trading (APM) With Integrated Risk Controls (APM:CA) - Stock Traders Daily Mon, 09 Mar 2026 18
• Andean Precious Metals to Pursue New York Stock Exchange Listing - TipRanks ue, 10 Mar 2026 11
• ad pepper media International (ETR:APM) Stock Price Down 5.6% - Time to Sell? - MarketBeat Fri, 06 Mar 2026 05
• Are Robust Financials Driving The Recent Rally In Andean Precious Metals Corp.'s (TSE:APM) Stock? - Yahoo Finance Fri, 09 Jan 2026 08
• Aptorum Group Receives Nasdaq Compliance Notification - Intellectia AI Fri, 06 Mar 2026 22
• Aptorum To Merge With DiamiR In All-stock Deal, Stock Up In Pre-market - Nasdaq Wed, 16 Jul 2025 07
• Aptorum Group Receives Nasdaq Notice Over Minimum Bid Price Deficiency - TipRanks Fri, 06 Mar 2026 22
• Andean Precious Metals (TSE:APM) Stock Price Up 3.8% - Should You Buy? - MarketBeat Fri, 20 Feb 2026 08
• We Think That There Are More Issues For Andean Precious Metals (TSE:APM) Than Just Sluggish Earnings - Yahoo Finance Wed, 20 Aug 2025 07
• Major Biotech Merger: Aptorum Group Targets Brain Health Market with DiamiR Acquisition - Stock Titan Wed, 16 Jul 2025 07
• Is It Too Late To Consider Andean Precious Metals (TSX:APM) After Its 3 Year Surge? - Yahoo Finance hu, 29 Jan 2026 08
• Dr. Laura Philips to join Aptorum's board at closing of DiamiR merger, expanding leadership ahead of Q4 2025 close - Stock Titan hu, 09 Oct 2025 07
• Insiders own 26% of APM Automotive Holdings Berhad (KLSE:APM) shares but private companies control 47% of the company - Yahoo Finance Mon, 06 Oct 2025 07
• Is Andean Precious Metals Corp.'s (TSE:APM) Recent Stock Performance Tethered To Its Strong Fundamentals? - simplywall.st Mon, 05 Jan 2026 08

• Income Statement
• Balance Sheet
• Cash Flow

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).